Dr. Advani Discusses Front-Line Brentuximab
Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.
Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.
Brentuximab is currently approved for Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin will not be beneficial for all subtypes of lymphoma, Advani says, but will be for CD30-positive lymphomas. This is an exciting potential development because about 30% of other T-cell lymphomas also express CD30.
Advani looking forward to the large randomized trial evaluating CHOP chemotherapy plus placebo compared to CHOP plus brentuximab.
